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T-cell lymphoma
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Background: To identify demographic and clinical characteristics associated with cases of hepatosplenic T-cell
lymphoma (HSTCL) in patients with Crohn’s disease, and to assess strength of evidence for a causal relationship
between medications and HSTCL in Crohn’s disease.
Methods: We identified cases of HSTCL in Crohn’s disease in studies included in a comparative effectiveness review
of Crohn’s disease medications, through a separate search of PubMed and Embase for published case reports, and
from the Food and Drug Administration (FDA) Adverse Event Reporting System (AERS). We used three causality
assessment tools to evaluate the relationship between medication exposure and HSTCL.
Results: We found 37 unique cases of HSTCL in patients with Crohn’s disease. Six cases were unique to the published
literature and nine were unique to AERS. Cases were typically young (<40 years of age) and male (86%). The most
commonly reported medications were anti-metabolites (97%) and anti-tumor necrosis factor alpha (anti-TNFa)
medications (76%). Dose and duration of therapy were not consistently reported. Use of aminosalicylates and
corticosteroids were rarely reported, despite the high prevalence of these medications in routine treatment. Using the
causality assessment tools, it could only be determined that anti-metabolite and anti-TNFa therapies were possible
causes of HSTCL in Crohn’s disease based on the data contained in the case reports.
Conclusion: Systematic reviews that incorporate case reports of rare lethal events should search both published
literature and AERS, but consideration should be given to the limitations of case reports. In this study, establishing a
causative effect other than ‘possible’ between anti-metabolite or anti-TNFa therapies and HSTCL was not feasible
because case reports lacked data required by the causality assessments, and because of the limited applicability of
causality assessment tools for rare irreversible events. We recommend minimum reporting requirements for case
reports to improve causality assessment and routine reporting of rare life-threatening events, including their absence, in
clinical trials to help clinicians determine whether rare adverse events are causally related to a medication.
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Crohn’s disease is an idiopathic, chronic, inflammatory
bowel disease that affects the gastrointestinal tract. An
estimated 565,000 to 720,000 people in the United States
have Crohn’s disease [1]. In the 1950s, corticosteroids
and sulfasalazine were adopted as the first immunosup-
pressive treatments for Crohn’s disease, followed by the
anti-metabolites, 6-mercaptopurine and azathioprine, in
the 1960s [2]. The twenty-first century has brought with
it the first biologic agent for Crohn’s disease, infliximab,
a monoclonal antibody against tumor necrosis factor
alpha (anti-TNFa). Adalimumab and certolizumab pegol
are the other approved anti-TNFa agents.
Hepatosplenic T-cell lymphoma (HSTCL) is a rare and
often fatal outcome associated with Crohn’s disease. A
boxed warning was issued in 2006 for an association be-
tween infliximab and HSTCL. As of October 2011, the
label for infliximab reads:
‘Postmarketing cases of fatal hepatosplenic T-cell lymph-
oma (HSTCL) have been reported in patients treated with
TNF blockers including infliximab. All infliximab cases
were reported in patients with Crohn’s disease or ul-
cerative colitis, the majority of whom were adolescent
or young adult males. All had received azathioprine or
6-mercaptopurine concomitantly with infliximab at or
prior to diagnosis (brand name changed to generic in
italics)’ [3].
Despite increasing concerns about the use of anti-
TNFa medications, there is no definitively established
causal mechanism for HSTCL. Risk factors for HSTCL
are thought to include young age, male gender, Crohn’s
disease, and renal transplantation [4]. However, HSTCL
has occurred in the absence of immunosuppressive
treatment and immunodeficiency [5]. Symptoms of
HSTCL include fever, cytopenias, and an enlarged
spleen and liver [4]. Because of the rarity of HSTCL,
cases are unlikely to be identified in trials. Case reports
leading to better understanding of Crohn’s disease pa-
tients who experience HSTCL may help to identify
those patients at increased risk. Causality assessment
tools developed for case reports can then be used to
determine the likelihood that a medication is causally
associated with HSTCL.
We aimed to identify demographic and clinical char-
acteristics and medication histories associated with
HSTCL in Crohn’s disease cases published in the peer-
reviewed literature or reported to the Food and Drug
Administration (FDA) Adverse Event Reporting Sys-
tem (AERS) database. We used three different causality
assessment tools to assess the strength of evidence
supporting a causal relationship between medication
exposures and HSTCL in Crohn’s disease. This project
was performed as part of a comparative effectiveness
review of treatments for Crohn’s disease [6]. We willalso discuss the implications of our findings for the use
of case reports in systematic reviews.
Methods
Literature search and identification of cases from the
published literature
PubMed and Embase were queried on 25 January 2011
using predetermined search strings that included the
terms ‘Crohn’s disease,’ ‘inflammatory bowel disease,’ and
‘hepatosplenic T cell lymphoma’ (see full search strings
in Additional file 1: Table S1). We included all study
types with human patients. Studies were excluded if they
were not written in English or if they did not include pa-
tients with Crohn’s disease who had developed HSTCL.
Additionally, all studies that met the inclusion criteria
for the original systematic review were included if they
specifically mentioned HSTCL. We also performed a
hand-search of references in relevant articles. To avoid
double counting of cases that had been reported mul-
tiple times in the literature, we checked the footnotes
and references, as well as the demographic and clinical
characteristics.
Search of the Food and Drug Administration (FDA)
Adverse Event Reporting System (AERS) database and
identification of AERS cases
The FDA AERS database was searched for all reported
cases of HSTCL from January 2004, the first year data is
available online, through December 2010. Only cases
that had Crohn’s disease listed as an indication for ther-
apy were included. To avoid double counting of cases
reported by multiple sources (such as by a treating phys-
ician and a pharmaceutical company), the case entries
were matched by case number. If the case number did
not match but the report had identical information for
three of five criteria (age at diagnosis, date of death,
diagnosis date, reporting country, sex), then this entry
was reported as a unique case, similar to previous efforts
to avoid duplicates using AERS [7].
Matching cases from the published literature with
AERS cases
We sought to distinguish cases reported in both the pub-
lished literature and AERS from those cases reported in
only one source, using the following information: age at
HSTCL diagnosis; date of HSTCL diagnosis or date of pub-
lication or AERS report when HSTCL date not reported;
sex; medication history; reporting country (AERS) or coun-
try of origin (published literature); and date of death
(AERS) or survival status or months of survival (published
literature) (see Additional file 2: Table S2). If a case report
from AERS and the literature matched on three of the five
criteria, then the case was reported as a single unique case
reported in both sources. We then identified cases reported
Table 1 Characteristics of published instruments
assessing causal relationship between medication
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tion to consider them a unique case reported in only one
source. Finally, some entries did not have sufficient details
to determine if they were a unique case. We recorded the
demographics of entries with insufficient reporting, but ex-








































Yes Yes NoCausality assessment
To evaluate the evidence supporting the association of
medication exposures with HSTCL, we used causality as-
sessment tools developed by the World Health Organization
(WHO), Naranjo et al., and Kramer et al. [8-10]. Two evalu-
ators (EC and SS) independently calculated the causality as-
sessment score for each medication used in each case and
then met to discuss and resolve by consensus differences be-
tween the scores.
Table 1 compares the characteristics and content of the
three causality assessments. The Naranjo and Kramer as-
sessments produced numerical scores that corresponded
with causal categories of definite, probable, possible, and
unlikely/doubtful. The WHO assessment assigns cases to


















n/a, not applicable; WHO, World Health Organization.Results
Search results and identification of unique cases
Of the 123 citations identified by the PubMed and
Embase searches, 19 case reports or case series [5,11-28]
and three conference-presentation abstracts [29-31] met
the inclusion criteria of reporting at least one Crohn’s
disease-related HSTCL case (Figure 1). Three additional
conference-presentation abstracts were identified through
a hand-search of the references of the included articles
[32-34]. No comparative studies that met the inclusion cri-
teria for the systematic review reported a case of HSTCL.
One prospective study reported specifically that no cases
of HSTCL were observed [35]. Thirty-four cases were
identified from the published literature with 28 having suf-
ficient information to be considered unique cases.
A search of the publicly available AERS data files yielded
139 patient identification numbers representing 50 unique
case numbers, which after matching yielded 34 cases with
31 having sufficient information to be considered unique.
After matching unique cases from the published lit-
erature with the unique cases from AERS, 37 total cases
were considered unique (22 from both sources, six
from the published literature only, and nine from AERS
only; Additional file 1: Table S1). Thirty-six HSTCL
cases were considered unique based on age, sex, and
medication exposures. An additional case was consid-
ered unique based on the case’s use of cyclosporine
even though age at HSTCL diagnosis and sex were notreported [32]. Nine cases had insufficient reporting
(Additional file 2: Table S2).
Demographics, presenting symptoms and survival
The 37 unique patients were young (84% of patients
were younger than age 40 years) and male (86%;
Table 2). Patients had Crohn’s disease for a mean of 10
years prior to their diagnosis of HSTCL (range: 4 to 35
years). All patients reporting any symptoms presented
with hepatosplenomegaly or splenomegaly (100%), and
approximately one-half presented with fever (47%) or
cytopenia (58%). The median length of survival among
the 26 cases with information was 7 months (range: 5
days to 9.7 years). HSTCL resulted in death for 65% of
patients. Survival was not reported for 30% of cases
and two patients were alive at the time of the case
Unique PubMed and 
EMBASE citations
123
Reported at least 1 
















No cases of Crohn’s 
disease-related 









22 identified from 
both sources
6 identified from 
published literature




6 identified from 
published literature









Figure 1 Identification of unique cases by PubMed and Embase searches. AERS, Adverse Event Reporting System; HSTCL, hepatosplenic
T-cell lymphoma.
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therapy and a bone marrow transplant, and another
patient at 20 months after HSTCL diagnosis.
Information about the patient’s race, Crohn’s disease
location, behavior, and severity was infrequently reported
in published case reports and case series. This informa-
tion is not requested in the AERS case report form. Race
was reported for two patients, both of whom were white
[15,25]. Five patients had information on disease loca-
tion: one patient had ileal disease [25], two patients had
ileocolonic disease [12,17], one patient had ileal and
perianal disease [15], and one patient had perianal dis-
ease [32]. Disease behavior was reported for one patient
who had inflammatory disease [14].
Medication history
The timeline in Figure 2 displays the report of new
HSTCL cases in patients with Crohn’s disease from 1998
through 2010, including the 37 unique cases and the
nine cases with insufficient information. Case exposure
patterns for biologic medications were similar to thetimeline of FDA approval for Crohn’s disease: 96% of
biologic exposures among the 37 unique cases involved
infliximab (approved in 1998), 29% adalimumab (ap-
proved in 2007), 4% natalizumab (approved in 2008), 4%
ustekinumab (not approved as of December 2012), and
thus far no affected patients had certolizumab pegol ex-
posure (approved in 2008). All cases that used a biologic
had also used infliximab, with the exception of one case
who used adalimumab only. The use of concurrent med-
ications or medications at the time of HSTCL diagnosis
cannot be summarized because this information was not
uniformly reported.
The most frequently reported medications used were
anti-metabolites and anti-TNFa agents (Table 3). Thirty-
six unique cases (97%) used an anti-metabolite and 28
cases (76%) used an anti-TNFa. Eight cases had used an
anti-metabolite without an anti-TNFa agent. One case
had used cyclosporine and an anti-metabolite. Of the pa-
tients who used anti-TNFa therapy, 27 cases (96%) had
also used an anti-metabolite, but not necessarily at the
same time. One patient who used anti-TNFa therapy
Table 2 Demographic and clinical characteristics of








Age at HSTCL diagnosis, years n = 36 n = 0
Mean 30 -
Median 26 -
Range 12 to 79 -
Disease duration, years n = 16 n = 0
Mean 10 -
Median 6 -
Range 4 to 35 -
Sex, n (%) n = 36 n = 6
Female 5 (14%) 1 (17%)
Survival, n (%) n = 26 n = 4
Died 24 (92%) 4 (100%)
Survived 2 (8%) 0 (0%)
Physical examination and laboratory
abnormalities at time of
HSTCL diagnosis, n (%)
n = 19 n = 1
Hepatosplenomegaly or splenomegaly 19 (100%) 1 (100%)
Fever 9 (47%) -
Cytopenia of any type 11 (58%) -
Altered liver enzymes and/or LDH 5 (26%) -
aInsufficient reporting on demographic information prevented us from
identifying if the cases were unique. With each patient characteristic heading,
the adjacent ‘n = x’ cells indicate the number of cases that reported on that
particular demographic. The percentages calculated for sex, survival, and
physical examination/laboratory abnormalities use this ‘n’ as the denominator.
HSTCL, hepatosplenic T-cell lymphoma, LDH, lactate dehydrogenase.
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base. This patient had infliximab and adalimumab ex-
posure (Additional file 2: Table S2).
Daily dose, duration, or cumulative dose of therapy
were not consistently reported (Table 3). The majority
of ‘mean doses’ were based on one to two patients.
Infliximab was the only medication where measures of
dose and duration were consistently provided. For the
anti-metabolites, information on duration of treatment
was also frequently provided, but information on daily
or cumulative dose less so. Aminosalicylate and cortico-
steroid exposures were less commonly reported, despite
the frequent use of aminosalicylates to treat colonic in-
flammatory disease and the use of corticosteroids to
treat disease flares.
Medication causality assessment
Table 4 summarizes causality assessments based on the
37 unique cases. Using three causality assessment tools,
the majority of medications received a score consistentwith ‘possible’ cause. All three tools had criteria for
rechallenge and dechallenge tests that could not be
performed for an irreversible outcome like lymphoma,
thus lowering the score. The tool of Kramer et al. in-
cluded criteria for the incidence of HSTCL, which has
not been estimated for Crohn’s disease, thus lowering
the score.
Scores calculated using the Naranjo method ranged
from 1 to 2 points, corresponding with ‘possible’ caus-
ation (1 to 4 points) for each patient who used each
medication. The items that contributed to the score for
most patients included a point for administration prior
to the development of HSTCL, and documentation of
histopathology to confirm HSTCL diagnosis. All patients
and medications lost one point because HSTCL has been
reported in the absence of medications [5].
Scores calculated using the Kramer method did vary be-
tween medication classes. Anti-metabolites, biologics, and
cyclosporine were determined to be a ‘possible’ cause of
HSTCL (0 to 3 points). All other medications scored −1
point, determined to be an ‘unlikely’ cause (< 0 points). The
variation in scores was due to previous reports of adverse
reactions with the medication and availability of the medi-
cation. Anti-metabolites and cyclosporine were scored 0
points because they have been linked to other lymphomas.
Natalizumab and ustekinumab were scored 0 points be-
cause they have been available for less than 20 years, so all
adverse reactions have not yet been described. Anti-TNFa
medications were scored 1 point because they have been
associated with other lymphomas and have been available
for less than 20 years. Antibiotics and corticosteroids re-
ceived scores of −1 point because the medications have
been available for long enough for most adverse reactions
to have been previously reported and they have not been
associated with lymphoma.
Assessments of causality using the WHO method pro-
vided determination of ‘possible’ causation. Because the
time required for development of HSTCL is unknown,
any medication administered before HSTCL diagnosis was
considered to be within a ‘reasonable’ time period leading
up to HSTCL development. Because HSTCL could have
been explained by another medication or Crohn’s disease
itself, each medication used for each patient met the cri-
terion for an alternative etiology.
Discussion
All medications were possibly related to HSTCL according
to at least one causality assessment tool. Anti-metabolites,
biologics, and cyclosporine were possibly related to HSTCL
according to all three causality assessment tools. Despite
the possible causal relationship found across three different
tools for these medications, only the anti-TNFas carry a
boxed warning for HSTCL. The label for azathioprine in-
cludes a boxed warning for malignancy with mention of




















































Figure 2 Timeline of medication approval by the Food and Drug Administration (FDA) and occurrence of hepatosplenic T-cell
lymphoma (HSTCL). Includes 37 unique cases and nine cases with insufficient reporting, for a total of 46 cases. Each box includes a unique case
by year the case was reported. The horizontal axis indicates the year the case was diagnosed. The numbers in each square are ordered oldest to
youngest age at HSTCL diagnosis. They match up to the numbers with detailed case information in Additional file 2: Table S2. Vertical arrows
indicate years that the particular medications were approved by the FDA. Ustekinumab is not approved by the FDA for Crohn’s disease. The
numbers within each box refer to case numbers in Additional file 2: Table S2. Patients were reported through 25 January 2011 (published) and
December 2010 (AERS). *Date of case reported as 2007 to 2008. **Date of case reported as 2000 to 2009. AERS, Adverse Event Reporting System;
FDA, Food and Drug Administration; HSTCL, hepatosplenic T-cell lymphoma.
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in the non-boxed warnings. The label for cyclosporine
mentions the risk of lymphoma in the boxed warnings,
but not HSTCL specifically. The labels for natalizumab
and ustekinumab do not mention lymphoma. The most
common demographic risk factors were male sex and
younger age, similar to previous studies [22,26,27]. No
comparative study from the main systematic review in-
cluded a case of HSTCL, and only one study specifically
mentioned that no HSTCL cases were observed.
The methods guides for systematic reviews of the
Evidence-based Practice Center (EPC) Program and the
Cochrane Collaboration recommend using case series
in some instances [36-38]. Based on the importance of
HSTCL to patients, HSTCL’s high mortality and the rar-
ity of HSTCL, we performed a separate search of the
published literature for HSTCL case reports and case
series, and searched AERS as part of a systematic review
for treatments of Crohn’s disease. Our rationale for in-
cluding cases is consistent with the recommendations
of the methods guides. Other systematic reviews haveincluded case reports and case series identified from the
literature or cases from AERS based on similar rationale
[39-43]. In contrast to many previous systematic re-
views, we searched both case sources. Searching AERS
yielded nine cases not identified in the published litera-
ture. However, because the majority of cases were iden-
tified in both AERS and the published literature, we had
to create a process to identify the overlapping cases.
Insufficient reporting prevented us from determining
the uniqueness of all identified cases. A few case reports
failed to include patient age or sex. Many cases identified
as unique did not include information on medication dose,
frequency, or dates of use, even though reporting systems
such the FDA AERS request this demographic and medi-
cation data on their submission forms [44]. Incomplete
reporting is also prevalent in case reports on other types
of adverse medication events, and calls have been made
for a standardized list of case report guidelines similar to
the checklists created by organizations for other types of
observational studies [45]. Other agencies beside the FDA
also request specific demographic, clinical, laboratory, and
Table 3 Medications used to treat Crohn’s disease prior to the diagnosis of hepatosplenic T-cell lymphoma (HSTCL)
among unique cases














Adalimumab 8 (22%) 920 (800 to 1040) 1.5 (120 days to 2.6 years) 11.5 (10 to 13)
n = 2 n = 2 n = 2
Infliximaba 27 (73%) 41 (10 to 120) mg/kg 1.8 (1 day to 6 years) 9 (1 to 24)
n = 7 n = 12 n = 17
Natalizumab 1 (3%) NR NR 3
Ustekinumab 1 (3%) NR NR NR
Certolizumab pegol 0
Anti-metabolites 365 (97%)
6-mercaptopurine 20 (54%) 94,508 (3,900 to 212,160) 4.8 (39 days to 8 years)
n = 4 n = 10
Azathioprine 23 (62%) 192,108 (1,450 to 301,125) 5.8 (39 days to 13.5 years)
n = 3 n = 17
Aminosalicylates 15 (41%)
Balsalazide 1 (3%) NR NR
Mesalamine 13 (35%) NR 5 (n = 1)
Sulfasalazine 2 (5%) NR 10 (n = 1)
Corticosteroids 22 (59%)
Budesonide 2 (5%) NR NR
Hydrocortisone 1 (3%) NR NR
Prednisone 14 (38%) NR NR
Prednisolone 5 (14%) NR 13 (n = 1)
Corticosteroid 4 (11%) NR 10 (n = 1)
Other medicationsb 15 (41%)
Antibioticsc 8 (22%) NR NR
Cyclosporine 1 (3%) NR NR
aAmong those that reported this data. Cumulative dose excludes cases that only provided mg/kg dosing but did not provide patient weight in kilograms and
those cases which reported a daily dose but did not report duration of treatment. bExcluding vitamin/mineral supplements. cThe antibiotics used included
ciprofloxacin, doxycycline, metronidazole, nitrofurantoin, and piperacillin/tazobactam. HSTCL, hepatosplenic T-cell lymphoma; NR, not reported.
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Nevertheless, no standard checklist exists for case
reporting, and journal requirements for case report con-
tent are variable [47].
The usefulness of case reports to identify potential ad-
verse medication events will be enhanced by a standardized
checklist for case reporting. Such a checklist should incorp-
orate information commonly requested for adverse event
reports and causality assessment, including: basic demo-
graphics, documentation of the use and timing of use of
the individual and concomitant medications used to treat
the condition (including absence of use), all other medica-
tions used by the patient, rechallenge and dechallenge in-
formation (including absence), laboratory results (including
serum medication levels), and diagnostic tests used toconfirm the adverse event. Reporting the complete list of
medications used by the cases, rather than focusing on
medications previously associated with the adverse events,
as was common in the case reports we identified, will also
aid in the understanding of drug interactions and the ad-
verse event. Modifying the AERS database to require these
elements for submission and standardizing the information
in case reports submitted to journals will help to match
AERS cases to the published cases, identify trends by items
like race that are not consistently reported, and improve
causality assessments. The suggested modifications are con-
sistent with the Institute for Safe Medication Practices’s
(ISMP) recommendation to update AERS to improve the
quality of reporting so that the FDA can make more
targeted safety warnings [48,49].
Table 4 Results of the published instruments assessing
causal relationship between medication exposure and








Adalimumab Possible Possible Possible
Certolizumab pegol No use reported in any case report
Infliximab Possible Possible Possible
Natalizumab Possible Possible Possible
Ustekinumab Possible Possible Possible
Anti-metabolites
6-mercaptopurine Possible Possible Possible
Azathioprine Possible Possible Possible
Aminosalicylates
Balsalazide Possible Unlikely Possible
Mesalamine Possible Unlikely Possible
Sulfasalazine Possible Unlikely Possible
Corticosteroids
Budesonide Possible Unlikely Possible
Hydrocortisone Possible Unlikely Possible
Prednisone Possible Unlikely Possible
Prednisolone Possible Unlikely Possible
Corticosteroid unspecified Possible Unlikely Possible
Other medications
Cyclosporine Possible Possible Possible
Metronidazole Possible Unlikely Possible
Nitrofurantoin Possible Unlikely Possible
Piperacillin/tazobactam Possible Unlikely Possible
Doxycycline Possible Unlikely Possible
Ciprofloxacin Possible Unlikely Possible
Possible, all cases reporting that medication received a score of ‘possible’
using that particular causality assessment; unlikely, all cases reporting that
medication received a score of ‘unlikely’ using that particular causality
assessment. WHO, World Health Organization.
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and almost uniformly fatal condition such as HSTCL was
challenging. Based on available data, we could not make
any causal assessments other than ‘possible’ for all medica-
tions. Some elements, such as rechallenge with medica-
tion, are not possible for events that rapidly progress to
mortality. Improvement of symptoms for cancer with
dechallenge is also rare, although regression of lymphoma
with withdrawal of azathioprine has been documented
[50]. Other items in the causality tools required more
complete reporting, such as serum medication levels or
details of the case confirmation, were not available for all
cases. Better case reporting and understanding how to
modify causality tools for use with irreversible adverseevents will assist in making causality assessments for rare
events from case reports. For events such as HSTCL that
likely have a complex, multifactorial etiology that may de-
velop over months to years, reporters should be prompted
to include more detailed information on patient medical
history (few of the reports had details on Crohn’s disease
severity and behavior), family history, and the absence of
use or past use of certain medications commonly used to
treat the underlying disease. This data could be requested
as part of the FDA’s existing enhanced safety surveillance
of TNFa-blockers and pediatric and young adult malig-
nancy, or even in routine submission of MedWatch forms
for adverse events such as malignancy [51]. Journals can
also request that authors provide this history when submit-
ting case reports on malignancies that are possibly associ-
ated with medications. Routine reporting of this additional
information may accelerate identification of other medica-
tions and risk factors associated with the adverse event.
Causal assessments can then be modified to incorporate
relevant biology and epidemiology and used to prioritize
which safety events should be studied further to estimate a
rate by medication use.
When possible causality has been established from case
reports, trials and observational studies can contribute in-
formation to estimate a rate of disease by medication use.
Trials and prospective studies may begin collecting infor-
mation on safety events like HSTCL. If trials and observa-
tional studies report the occurrence of these rare events
and details of the active or passive collection process, the
rate of HSTCL can be estimated. For trials and compara-
tive medication studies, a rate by medication use can be
calculated by pooling the studies. Understanding the rate
of disease, which is not possible from case reports, can help
patients and their caretakers make better treatment deci-
sions. Trials and observational studies should also attempt
to collect specific details about the events. For example,
the TREAT Registry, a Phase IV study for infliximab,
reported a case of fatal peripheral T-cell lymphoma with
infliximab and immunomodulator use within 6 months
of death [52]. Readers cannot determine whether the
T-cell lymphoma was HSTCL because details were not
provided in the main text of the publication or the sup-
plemental table. By providing more detailed informa-
tion about the cause of death, particularly when a death
may be due to a black box warning-related event, Phase
IV studies could help to improve understanding of the
rate of life-threatening events such as HSTCL in these
important safety studies.
Conclusions
Consistent with FDA safety warnings, we confirmed
that anti-metabolites, anti-TNFas, and cyclosporine
have a possible causal association with HSTCL. We
were unable to assign any score other than ‘possible’
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in data reported in case reports and difficulty in obtaining
rechallenge and dechallenge data for a fatal event such as
HSTCL. Minimum reporting requirements for peer-
reviewed literature and AERS will help facilitate the use of
case reports to identify adverse events and assess causality.
Reporting the absence of HSTCL in trials and cohort stud-
ies will provide information to estimate a rate of HSTCL
occurrence by medication use. Intentional assessment will
be particularly useful in studies that include children and
young adults who appear to be at a greater risk of HSTCL.
Our findings provide support for the development and
adoption of case report guidelines, a topic that will be
discussed at the next International Congress on Peer Re-
view and Biomedical Publication [53]. Standards for
collecting additional patient history in case reports and
modifying causality assessment tools for irreversible events
such as a fatal lymphoma will assist in making causal as-
sessments using case reports.Additional files
Additional file 1: Supplemental Table 1. Search strings used to
identify cases in PubMed and Embase.
Additional file 2: Supplemental Table 2. Case series: characteristics of
individual cases identified in the literature and Adverse Event Reporting
System.
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